Shots:
- The companies enter into a license agreement for the Preserflo MicroShunt superseding the previous collaboration between the two parties
- Glaukos get exclusive commercialization rights for the MicroShunt in the US, Australia, New Zealand, Canada, Brazil, Mexico and the remainder of Latin America and gain full control over all development activities for the MicroShunt in the same territories, including development and regulatory activities in the US
- Santen will continue to manufacture & supply the MicroShunt for the Glaukos territories and lead development & commercialization activities elsewhere. In Jun’2020, Santen has submitted PMA to the US FDA
Click here to read full press release/ article | Ref: BUSINESS WIRE | Image: Glaukos
The post Glaukos Expands its Partnership with Santen for Preserflo MicroShunt first appeared on PharmaShots.
